Brian Leyland‐Jones

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.5K citations · Full text

Medicine, Oncology, Pharmacology +10

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text

Medicine, Oncology, Pharmacology +16

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Martine Piccart, Richard D. Gelber et al. · The Lancet · 2017 · 1K citations · Full text

Medicine, Immunology, Oncology +17

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

Jason K. Sicklick, Shumei Kato, Ryosuke Okamura et al. · Nature Medicine · 2019 · 720 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Brian Leyland‐Jones, Marek Pawlicki, Tadeusz Pieńkowski et al. · Journal of Clinical Oncology · 2005 · 665 citations · Full text

Medicine, Oncology, Pharmacology +15